Unlocking the Supraciliary Space

Targeting uveoscleral outflow may result in greater IOP reduction with fewer complications.

Glaucoma Physician June 1, 2025 Page(s): 13-15

Clinical Report: Unlocking the Supraciliary Space

Overview

Targeting the supraciliary space for glaucoma treatment may enhance intraocular pressure (IOP) reduction while minimizing complications associated with traditional surgical methods. Recent developments in microinvasive glaucoma surgeries (MIGS) highlight the potential of devices like the MINIject to improve outcomes for patients with primary open-angle glaucoma.

Background

Elevated intraocular pressure is the primary risk factor for glaucoma progression, making effective management crucial. Traditional surgical interventions, while effective, carry significant risks of complications. The exploration of the supraciliary space as a target for innovative drainage strategies represents a promising alternative to conventional approaches, potentially offering safer and more effective options for IOP reduction.

Data Highlights

No numerical data available in the source material.

Key Findings

Supraciliary MIGS devices, such as the MINIject, are designed to enhance aqueous humor outflow and reduce IOP.
The CyPass microstent was the first FDA-approved supraciliary device but was withdrawn due to concerns over endothelial cell loss.
The MINIject has shown promising results in European trials, with a reported mean IOP reduction of approximately 39%.
The STAR-V clinical trial is currently evaluating the safety and effectiveness of the MINIject in the United States.
Guidelines emphasize the importance of targeting the uveoscleral pathway for glaucoma management, highlighting the need for ongoing surveillance of new devices.

Clinical Implications

Clinicians should consider the supraciliary space as a viable target for glaucoma treatment, particularly for patients who are not adequately managed by medical therapy or traditional surgical options. The development of devices like the MINIject may offer a safer alternative with fewer complications, warranting further investigation and potential integration into clinical practice.

Conclusion

The exploration of the supraciliary space for glaucoma treatment represents a significant advancement in the management of elevated IOP. Continued research and clinical trials will be essential to establish the long-term safety and efficacy of these innovative approaches.

PentaVision

Glaucoma Physician